Newsletter | August 28, 2026

08.28.26 -- How Point-Of-Need Execution Protects Ocular Endpoints

VIDEO

Getting To A First Product Approval With Celcuity's Brian Sullivan

Brian Sullivan of Celcuity shares lessons from Revtorpyk’s first FDA approval and explains why targeting an untreated disease mechanism may outperform a single-mutation focus.

INDUSTRY INSIGHTS

The State Of eSource Adoption In Clinical Trials

Learn how eSource-ready sites are improving trial efficiency, reducing site burden, and becoming essential to modern clinical trial execution.

How Point-Of-Need Execution Protects Ocular Endpoints

Reduce operational risk in ophthalmic trials with point-of-need execution. Discover how mobile clinics, specialized teams, and single-call accountability protect endpoint quality and study timelines.

Busy Quarter For Gene, Cell, RNA Therapies

Explore how Q2 brought renewed momentum for gene, cell, and RNA therapies and grew confidence in the future of advanced medicine with rising approvals, expanding pipelines, and increased investment.

CDMOs Evolve IT Validation Strategies To Stay Ahead

CDMOs are modernizing IT validation by adopting risk-based, lifecycle approaches, digital tools, and continuous assurance models to improve compliance, efficiency, scalability, and data integrity.

Closing The Gaps: Strengthening Safety Data Flow In Outsourced Clinical Trials

Outsourced clinical trials risk safety missteps when communication falters. Learn how a clear, detailed data-flow process affects your safety decisions.

Connect With Life Science Leader: